Prostate‐specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique

Aims:  To determine prostate‐specific membrane antigen (PSMA) expression in normal tissues and in 3161 benign and malignant tumours and subsequently to define its sensitivity and specificity in prostatic adenocarcinoma (PaC).

[1]  R Y Ball,et al.  Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs , 2005 .

[2]  P. Thorpe,et al.  Anti‐tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate‐specific membrane antigen , 2004, The Prostate.

[3]  J. Quian,et al.  Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 2004, Histology and histopathology.

[4]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  G. Sauter,et al.  Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. , 2003, Human pathology.

[6]  N. Bander,et al.  Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.

[7]  A. Partin,et al.  Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. , 2003, Urology.

[8]  M. Pelte,et al.  Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. , 2002, Human pathology.

[9]  H. Samaratunga,et al.  Expression analysis of δ‐catenin and prostate‐specific membrane antigen: Their potential as diagnostic markers for prostate cancer , 2002, International journal of cancer.

[10]  N. Goldstein.  Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. , 2002, American journal of clinical pathology.

[11]  Sam S. Chang,et al.  The clinical role of prostate-specific membrane antigen (PSMA). , 2002, Urologic oncology.

[12]  H. Moch,et al.  Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies , 2001, The Journal of pathology.

[13]  V. Reuter,et al.  Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. , 2001, Urology.

[14]  V. Reuter,et al.  Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. , 2001, Urology.

[15]  B. Tombal,et al.  Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[17]  V. Reuter,et al.  Immunophenotype of High-Grade Prostatic Adenocarcinoma and Urothelial Carcinoma , 2000, Modern Pathology.

[18]  V. Reuter,et al.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[20]  V. Paradis,et al.  Molecular expression of PSMA mRNA and protein in primary renal tumors , 1999, International journal of cancer.

[21]  D. Bostwick,et al.  Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.

[22]  F. Vicini,et al.  The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure. , 1998, American journal of clinical pathology.

[23]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[24]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  B. Suffoletto,et al.  Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  J. Coyle,et al.  Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[28]  J. Epstein,et al.  PSA and PAP as immunohistochemical markers in prostate cancer. , 1993, The Urologic clinics of North America.

[29]  J. Masters,et al.  Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. , 1985, British journal of urology.

[30]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.